Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (5098)	12/11/2001 9:19:39 AM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Thanks, BulbaMan. One thing worth adding is that in biotech there are smart shorts (like Avalon) and dumb shorts (like Anthony@ etc.). When you have the dumb shorts and their even dumber followers in a stock things tend to get unpleasant. But I think worst of all are the sleazier hedge funds who are smart enough to make a convincing (but specious) argument. Short positions in many biotechs have been climbing. For example, look at SCIO, an Avalon short. Both the price and the short position have been showing a steady increase since the September low, with the November short position a massive 7.7m shares. One nice place to look at short positions over time is: viwes.com I noticed MOGN has had a dramatic increase in short position in November, doubling from October. Remember always that raw short numbers can be very misleading because often large short positions are hedges against convertible or option/warrant holdings. Peter